塞尔珀卡丁尼:第一个被批准的选择性RET抑制剂
Larissa C B Oliveira1, Lois M Mulligan1
1Division of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.
作为一种新型RET抑制剂,Selpercatinib有效向RET融合蛋白和突变蛋白. 这种FDA批准的疗法阻断了癌细胞的增殖和生存信号,
科学领域:
- 癌症学
- 分子生物学
- 药理学
背景情况:
- 当被融合或突变改变时,RET原型瘤基因在各种癌症中起着关键作用.
- 准RET信号通路是癌症治疗的一个有前途的策略.
研究的目的:
- 介绍Selpercatinib,一种强效和选择性的RET激酶抑制剂.
- 突出其抑制瘤性RET变化的作用机制.
主要方法:
- 塞尔帕卡提尼布与RET激酶的活性部位结合.
- 它可以抑制构成二元化的RET融合蛋白和激活点突变物.
主要成果:
- 塞尔珀卡丁尼有效地阻断了癌细胞增殖和存活所必需的下游信号.
- 这代表了针对癌症治疗的重大进步.
结论:
- 塞尔珀卡提尼布是FDA批准的第一个针对瘤RET融合蛋白的药物.
- 这种选择性RET抑制剂为RET改变的癌症患者提供了新的治疗选择.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
